Longitudinal Assessment of Imatinib’s Effect on the Blood–Brain Barrier After Ischemia/Reperfusion Injury with Permeability MRI

Translational Stroke Research

Volumn 6, Issue 1, 2015, Pages 39-49

  Merali, Zamir ^a   Leung, Jackie ^a   Mikulis, D ^b   Silver, F ^c   Kassner, Andrea ^a,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acute stroke; Blood brain barrier; Brain edema; Brain ischemia; Focal ischemia; MRI

Indexed keywords

IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN ZO1; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TJP1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; EXTRAVASATION; LONGITUDINAL STUDY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; TISSUE PRESERVATION; ANIMAL; CEREBRAL ARTERY DISEASE; COMPLICATION; DRUG EFFECTS; METABOLISM; NEUTROPHIL CHEMOTAXIS; PERMEABILITY; SPRAGUE DAWLEY RAT; STROKE;

ANIMALS; BENZAMIDES; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; INFARCTION, MIDDLE CEREBRAL ARTERY; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; NEUTROPHIL INFILTRATION; NF-KAPPA B; PERMEABILITY; PIPERAZINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; STROKE; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84921362221     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-014-0358-6     Document Type: Article

References (41)

1. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28(11):2109–18.
2. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008;371(9624):1612–23.
3. Xing C, Hayakawa K, Lok J, Arai K, Lo EH. Injury and repair in the neurovascular unit. Neurol Res. 2012;34(4):325–30.
4. Kassner A, Roberts T, Taylor K, Silver F, Mikulis D. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. Am J Neuroradiol. 2005;26(9):2213–7.
5. Kassner A, Thornhill R. Measuring the integrity of the human blood–brain barrier using magnetic resonance imaging. Methods Mol Biol. 2011;686:229–45.
6. Armstead WM, Nassar T, Akkawi S, Smith DH, Xiao-Han C, Cines DB, et al. Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci. 2006;9(9):1150–5.
7. Sandoval KE, Witt KA. Blood–brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis. 2008;32(2):200–19.
8. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J. MMP-9-positive neutrophil infiltration is associated to blood–brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke. 2008;39(4):1121–6.
9. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008;39(8):2249–56.
10. Abbruscato TJ, Lopez SP, Mark KS, Hawkins BT, Davis TP. Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. J Pharm Sci. 2002;91(12):2525–38.
11. Jiao H, Wang Z, Liu Y, Wang P, Xue Y. Specific role of tight junction proteins claudin-5, occludin, and ZO-1 of the blood–brain barrier in a focal cerebral ischemic insult. J Mol Neurosci. 2011;44(2):130––9. Jun 2011.
12. Abrams MB, Nilsson I, Lewandowski SA, Kjell J, Codeluppi S, Olson L, et al. Imatinib enhances functional outcome after spinal cord injury. PLoS One. 2012;7(6):e38760.
13. Su E, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood–brain barrier integrity during ischemic stroke. Nat Med. 2008;14:731.
14. Ma Q, Huang B, Khatibi N, Rolland 2nd W, Suzuki H, Zhang JH, et al. PDGFR-alpha inhibition preserves blood–brain barrier after intracerebral hemorrhage. Ann Neurol. 2011;70(6):920–31.
15. Adzemovic MZ, Zeitelhofer M, Eriksson U, Olsson T, Nilsson I. Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood–brain barrier integrity and by modulating the peripheral immune response. PLoS One. 2013;8(2):e56586.
16. Deli MA, Ábrahám CS, Kataoka Y, Niwa M. Permeability studies on in vitro blood–brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol. 2005;25(1):59–127.
17. Hoffmann A, Bredno J, Wendland MF, Derugin N, Hom J, Schuster T, et al. Validation of in vivo magnetic resonance imaging blood–brain barrier permeability measurements by comparison with gold standard histology. Stroke. 2011;42(7):2054–60.
18. Durukan A, Tatlisumak T. Acute ischemic stroke: Overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol, Biochem Behav. 2007;87(1):179–97.
19. Liu S, Zhen G, Meloni BP, Campbell K, Winn HR. Rodent stroke model guidelines for preclinical stroke trials (1st edition). J Exp Stroke Transl Med. 2009;2(2):2–27.
20. Kriz J. Inflammation in ischemic brain injury: timing is important. Crit Rev Neurobiol. 2006;18(1–2):145–57.
21. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111(8):4022–8.
22. Uluç K, Miranpuri A, Kujoth GC, Aktüre E, Başkaya MK. Focal cerebral ischemia model by endovascular suture occlusion of the middle cerebral artery in the rat. J Vis Exp. 2011;05(48):e1978.
23. Takano K, Tatlisumak T, Bergmann AG, Gibson III DG, Fisher M. Reproducibility and reliability of middle cerebral artery occlusion using a silicone-coated suture (Koizumi) in rats. J Neurol Sci. 1997;153(1):8–11.
24. Vidarsson L, Thornhill RE, Liu F, Mikulis DJ, Kassner A. Quantitative permeability magnetic resonance imaging in acute ischemic stroke: how long do we need to scan? Magn Reson Imaging. 2009;27(9):1216–22.
25. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3(1):1–7.
26. Gerriets T, Stolz E, Walberer M, Müller C, Kluge A, Bachmann A, et al. Noninvasive quantification of brain edema and the space-occupying effect in rat stroke models using magnetic resonance imaging. Stroke. 2004;35(2):566–71.
27. Radu M, Chernoff J. An in vivo assay to test blood vessel permeability. J Vis Exp. 2013;73:e50062.
28. Garcia JH, Wagner S, Liu K, Hu X. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats: statistical validation. Stroke. 1995;26(4):627–35.
29. Ciarcia R, Vitiello MT, Galdiero M, Pacilio C, Iovane V, d'Angelo D, et al. Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. J Cell Physiol. 2012;227(6):2798–803.
30. Watson PM, Anderson JM, Vanltallie CM, Doctrow SR. The tight-junction-specific protein ZO-l is a component of the human and rat blood–brain barriers. Neurosci Lett. 1991;129(1).
31. Neumann-Haefelin T, Kastrup A, de Crespigny A, Yenari MA, Ringer T, Sun GH, et al. Serial MRI after transient focal cerebral ischemia in rats: dynamics of tissue injury, blood–brain barrier damage, and edema formation. Stroke. 2000;31(8):1965–73.
32. Xi G, Keep RF, Hua Y, Xiang J, Hoff JT. Attenuation of thrombin-induced brain edema by cerebral thrombin preconditioning. Stroke. 1999;30(6):1247–55.
33. Berti R, Williams AJ, Moffett JR, Hale SL, Velarde LC, Elliott PJ, et al. Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia–reperfusion brain injury. J Cereb Blood Flow Metab. 2002;22(9):1068–79.
34. Nurmi A, Lindsberg PJ, Koistinaho M, Zhang W, Juettler E, Karjalainen-Lindsberg ML, et al. Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke. 2004;35(4):987–91.
35. Carroll JE, Hess DC, Howard EF, Hill WD. Is nuclear factor-kappaB a good treatment target in brain ischemia/reperfusion injury? Neuroreport. 2000;11(9):R1–4.
36. Zhang L, Zhang ZG, Zhang RL, Lu M, Adams J, Elliott PJ, et al. Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke. 2001;32(12):2926–31.
37. Hill WD, Hess DC, Carroll JE, Wakade CG, Howard EF, Chen Q, et al. The NF-kappaB inhibitor diethyldithiocarbamate (DDTC) increases brain cell death in a transient middle cerebral artery occlusion model of ischemia. Brain Res Bull. 2001;55(3):375–86.
38. Kim E, Matsuse M, Saenko V, Suzuki K, Ohtsuru A, Mitsutake N, et al. Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in anaplastic thyroid carcinoma cells. Thyroid. 2012;22(7):717–24.
39. Schofield ZV, Woodruff TM, Halai R, Wu MC, Cooper MA. Neutrophils — a key component of ischemia reperfusion injury. Shock. 2013 Oct 1.
40. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab. 1999;19(8):819–34.
41. Stanimirovic D, Satoh K. Inflammatory mediators of cerebral endothelium: a role in ischemic brain inflammation. Brain Pathol. 2000;10(1):113–26.